

Letter by Pirson et al Regarding Article, "Results From DEFUSE 3 Good Collaterals Are Associated With Reduced Ischemic Core Growth but Not Neurologic Outcome"

Citation for published version (APA):

Pirson, F. A. V., van Zwam, W. H., & van Oostenbrugge, R. J. (2019). Letter by Pirson et al Regarding Article, "Results From DEFUSE 3 Good Collaterals Are Associated With Reduced Ischemic Core Growth but Not Neurologic Outcome". *Stroke*, *50*(6), E164-E164. <https://doi.org/10.1161/STROKEAHA.119.025419>

Document status and date:

Published: 01/06/2019

DOI:

[10.1161/STROKEAHA.119.025419](https://doi.org/10.1161/STROKEAHA.119.025419)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 01 Dec. 2024

Letter to the Editor

Stroke welcomes Letters to the Editor and will publish them, if suitable, as space permits. Letters must reference a Stroke published-ahead-of-print article or an article printed within the past 4 weeks. The maximum length is 750 words including no more than 5 references and 3 authors. Please submit letters typed double-spaced. Letters may be shortened or edited.

Letter by Pirson et al Regarding Article, “Results From DEFUSE 3 Good Collaterals Are Associated With Reduced Ischemic Core Growth but Not Neurologic Outcome”

To the Editor:

With great interest, we read the study by de Havenon et al¹ on the association of collaterals with ischemic core growth and neurological outcome in stroke patients with large vessel occlusion in the late time window (6–16 hours from last known well). In this study, the authors confirm the well-known association of collaterals with smaller infarct core volumes and reduced infarct core growth. However, the interaction between collaterals and treatment effect on functional outcome (modified Rankin Scale score, 0–2) could not be found.

In this study, the lack of interaction between collaterals and treatment effect on outcome is considered as an unexpected finding. In our opinion, this finding should be interpreted with caution for several reasons. First, the small and highly selected study population of patients with a very small ischemic core at baseline (median 9.8 [interquartile range, 1.7–23.4]) may have prevented a translation from infarct size to functional outcome, as would have been expected.² This highly selected study population is also reflected in a low percentage of absent (1.5%) and poor collaterals (25%), as mentioned by the authors. To fully investigate the association between collaterals and outcome, a cohort with a wider spread in collaterals is recommended.

Second, at baseline, the volume of the perfusion lesion in the group of poor collaterals was significantly larger than in the group of good collaterals. Larger perfusion deficit corresponds with more salvageable tissue and consequently higher expected clinical benefit. For this difference at baseline, no correction model was suggested by the authors.

Finally, collaterals were rated with the binary modified Tan scale. In a post hoc analysis of the MR CLEAN trial (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands),³ using a 4-point collateral score based on the method of Tan, a shift in the distribution on modified Rankin Scale in favor of the intervention group across all collateral grades has been observed, with the exception of the patient group with absent collaterals. The association between collaterals and neurological outcome may have been diminished due to a dichotomized measure in the study of de Havenon et al,¹ especially when the relatively small sample size of this study is taken into consideration.

We agree with the authors that further study is needed to better understand the role of collaterals for anterior circulation large vessel occlusion stroke patients in the late therapeutic window, but we consider it of clinical importance to investigate the full spectrum of collaterals in the late time window (6–24 hours after last known well). By using a more pragmatic approach and broader inclusion criteria, patients with a much wider range of

collaterals, and infarct core volumes, may be included in the MR CLEAN LATE trial (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands for Late Arrivals).

Sources of Funding

MR CLEAN LATE (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands for Late Arrivals) is subsidized by Netherlands Cardiovascular Research Initiative (CVON2015-01: CONTRAST), an initiative of the Dutch Heart Foundation, by the Brain Foundation Netherlands (HA2015.01.06), and by Health Holland, Top Sector Life Sciences & Health (LSHM17016), Stryker, Cerenovus, ZonMW, and of Medtronic.

Disclosures

Dr van Oostenbrugge and Dr van Zwam are the principal investigators of the MR CLEAN LATE trial (Multicenter Randomized Clinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands for Late Arrivals). Dr van Zwam reports personal fees from Stryker, personal fees from Cerenovus (paid to institution). Dr Pirson is coordinating investigator of the MR CLEAN LATE.

F. Anne V. Pirson, MD

Department of Neurology

Maastricht University Medical Center, Maastricht, the Netherlands

Wim H. van Zwam, MD, PhD

Department of Radiology

Maastricht University Medical Center, Maastricht, the Netherlands

Robert J. van Oostenbrugge, MD, PhD

Department of Neurology

Maastricht University Medical Center, Maastricht, the Netherlands

on behalf of MR CLEAN LATE executive committee

References

1. de Havenon A, Mlynash M, Kim-Tenser MA, Lansberg MG, Leslie-Mazwi T, Christensen S, et al. Results from DEFUSE 3: good collaterals are associated with reduced ischemic core growth but not neurologic outcome. *Stroke*. 2019;50:632–638. doi: 10.1161/STROKEAHA.118.023407
2. Boers AMM, Jansen IGH, Beenen LFM, Devlin TG, San Roman L, Heo JH, et al. Association of follow-up infarct volume with functional outcome in acute ischemic stroke: a pooled analysis of seven randomized trials. *J Neurointerv Surg*. 2018;10:1137–1142. doi: 10.1136/neurintsurg-2017-013724
3. Berkhemer OA, Jansen IG, Beumer D, Fransen PS, van den Berg LA, Yoo AJ, et al; MR CLEAN Investigators. Collateral status on baseline computed tomographic angiography and intra-arterial treatment effect in patients with proximal anterior circulation stroke. *Stroke*. 2016;47:768–776. doi: 10.1161/STROKEAHA.115.011788

(*Stroke*. 2019;50:e164. DOI: 10.1161/STROKEAHA.119.025419.)

© 2019 American Heart Association, Inc.

Stroke is available at <https://www.ahajournals.org/journal/str>

DOI: 10.1161/STROKEAHA.119.025419